Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia

详细信息    查看全文

• 作者：Burak Deveci ; Aysegul Kurtoglu ; Erdal Kurtoglu ; Ozan Salim…
• 关键词：Thalassemia ; Glomerular ; Tubular renal damage
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：95
• 期：3
• 页码：375-381
• 全文大小：279 KB
• 参考文献：1.Old J, Angastiniotis M, Eleftheriou A, et al (2013) Prevention of thalassaemias and other haemoglobin disorders. Volume 1: principles. Nicosia, Cyprus: Thalassaemia International Federation
  2.Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86:480–487PubMedCentral CrossRef PubMed
  3.Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92:583–588CrossRef PubMed
  4.Pennell DJ, Udelson JE, Arai AE, American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging et al (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128:281–308CrossRef PubMed
  5.Haddad A, Tyan P, Radwan A, Mallat N, Taher A (2014) β-thalassemia intermedia: a bird’s-eye view. Turk J Haematol 31:5–16PubMedCentral CrossRef PubMed
  6.Cusmà Piccione M, Piraino B, Zito C et al (2013) Early identification of cardiovascular involvement in patients with β-thalassemia major. Am J Cardiol 112:1246–1251CrossRef PubMed
  7.Quinn CT, Johnson VL, Kim HY, Thalassemia Clinical Research Network et al (2011) Renal dysfunction in patients with thalassaemia. Br J Haematol 153:111–117PubMedCentral CrossRef PubMed
  8.Bhandari S, Galanello R (2012) Renal aspects of thalassaemia a changing paradigm. Eur J Haematol 89:187–197CrossRef PubMed
  9.Ziyadeh FN, Musallam KM, Mallat NS, Mallat S, Jaber F, Mohamed AA, Koussa S, Taher AT (2012) Glomerular hyperfiltration and proteinuria in transfusion-independent patients with β-thalassemia intermedia. Nephron Clin Pract 121:c136–c143CrossRef PubMed
  10.Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C (2012) Renal function in patients with β-thalassaemia major: a long-term follow-up study. Nephrol Dial Transplant 27:3547–3551CrossRef PubMed
  11.Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW (2013) Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 9:385–398CrossRef PubMed
  12.Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31:673–689CrossRef PubMed
  13.Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE (2000) Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 11:1882–1888PubMed
  14.Ikeda A, Konta T, Takasaki S et al (2009) In a non-diabetic Japanese population, the combination of macroalbuminuria and increased urine beta 2-microglobulin predicts a decline of renal function: the Takahata study. Nephrol Dial Transplant 24:841–847CrossRef PubMed
  15.Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975CrossRef PubMed
  16.Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, de Jong PE, Grobbee DE, Crijns HJ, van Gilst WH (2000) Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 21:1922–1927CrossRef PubMed
  17.Huang M, Matsushita K, Sang Y, Ballew SH, Astor BC, Coresh J (2015) Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 65:58–66PubMedCentral CrossRef PubMed
  18.Jackson CE, Solomon SD, Gerstein HC et al (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550CrossRef PubMed
  19.Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139:901–906CrossRef PubMed
  20.Solomon SD, Lin J, Solomon CG, Prevention of Events With ACE Inhibition (PEACE) Investigators et al (2007) Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116:2687–2693CrossRef PubMed
  21.Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426CrossRef PubMed
  22.Palatini P (2012) Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 27:1708–1714CrossRef PubMed
  23.Türkiye Kan Merkezleri ve Transfüzyon Derneği (2011) Ulusal Kan ve Kan ürünleri rehberi. Türkiye Kan Merkezleri ve Transfüzyon Derneği, Istanbul
  24.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef
  25.Levey AS, Stevens LA, Schmid CH, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMedCentral CrossRef PubMed
  26.Sadeghi-Bojd S, Hashemi M, Karimi M (2008) Renal tubular function in patients with β-thalassaemia major in Zahedan, southeast Iran. Singap Med J 49:410–412
  27.Hamed EA, El Melegy NT (2010) Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr 36:39PubMedCentral CrossRef PubMed
  28.Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M (2010) Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol 123:148–152CrossRef PubMed
  29.Fibach E, Rachmilewitz EA (2010) The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci 1202:10–16CrossRef PubMed
  30.Ruggiero L, De Sanctis V (1998) Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients. J Pediatr Endocrinol Metab 11:773–778PubMed
  31.Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38:571–575PubMedCentral CrossRef PubMed
  32.Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164–1172PubMed
  33.Sauter M, Jülg B, Porubsky S, Cohen C, Fischereder M, Sitter T, Schlondorff D, Gröne HJ (2006) Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47:1075–1080CrossRef PubMed
  34.Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D (2003) Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41, E18CrossRef PubMed
  35.Pfister T, Atzpodien E, Bohrmann B, Bauss F (2005) Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97:374–381CrossRef PubMed
  36.Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233CrossRef PubMed
  37.Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, Sattar N, Zukowska-Szczechowska E, Dominiczak AF (2007) Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 71:816–821CrossRef PubMed
  
• 作者单位：Burak Deveci (1)
  Aysegul Kurtoglu (2)
  Erdal Kurtoglu (3)
  Ozan Salim (4)
  Tayfur Toptas (5)
  
  1. Department of Hematology, Ali Osman Sönmez Oncology Hospital, Bursa, Turkey
  2. Department of Biochemistry, Antalya Training and Research Hospital, Antalya, Turkey
  3. Department of Hematology, Antalya Training and Research Hospital, Antalya, Turkey
  4. Department of Hematology, Akdeniz University Hospital, Antalya, Turkey
  5. Department of Hematology, Marmara University Hospital, Pendik, 34899, Istanbul, Turkey
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Urinary albumin to creatinine (ACR) and beta2 microglobulin to creatinine ratios (BCR) are the surrogate and robust markers of renal glomerulopathy and tubulopathy, respectively. These markers predict short-term renal deterioration and mortality in various conditions. We aimed to assess the frequency and predictors of glomerular and tubular defects, renal impairment, and hyperfiltration in 96 adult patients with beta thalassemia intermedia and major. ACR > 300 mg/g creatinine and BCR > 300 μg/g creatinine were used to define the renal glomerular and tubular damages, respectively. Glomerular filtration rate (eGFR_creat) was estimated according to 2009 the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Decreased eGFR_creat was defined as less than 60 mL/min per 1.73 m2. Renal glomerular and/or tubular defects were observed in about 68.8 % of all patients. Forty percent of patients had glomerular hyperfiltration. None of the patients had a decreased eGFR_creat. T2* value ≤20 msec on cardiac magnetic resonance (cMR) was the only independent predictor of glomerular damage (p = 0.013). Use of alendronate was associated with less renal tubular damage (p = 0.007). Female gender and previous history of splenectomy were the independent predictors of glomerular hyperfiltration in multivariate analysis (p < 0.001 and p = 0.040, respectively). Renal tubular and glomerular damage is frequent in adult patients with thalassemia intermedia and major. T2* value on cMR was the only independent predictor of glomerular damage. However, since we did not explore all the parameters of iron, it is not possible to draw a definite conclusion about the association of cMR and glomerular damage. There is no association with cardiac iron overload/accumulation and tubular damage or hyperfiltration. Keywords Thalassemia Glomerular Tubular renal damage